Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07539454 · ClinicalTrials.gov registry record · Phase 2
Nirogacestat in Patients With Kaposi Sarcoma
A Phase 2 study, sponsored by AIDS Malignancy Consortium.
- Not yet
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
NCT07539454: Clinical Trial Phase 2 study, sponsored by AIDS Malignancy Consortium.
NCT07539454 is a Phase 2 study that has not yet begun recruiting, run by AIDS Malignancy Consortium. The registered enrollment target is 28 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (79% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07539454, a Phase 2 study, has not yet begun recruiting, sponsored by AIDS Malignancy Consortium.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
Study Summary
This phase II trial studies how well nirogacestat works in treating patients with skin Kaposi sarcoma (KS). Several anti-cancer drugs work well in treating KS, but there is no treatment that cures KS. Nirogacestat binds to a protein called gamma secretase, which blocks the activation of other proteins called Notch receptors. Blocking these proteins may help keep tumor cells from growing and may kill them. Nirogacestat is a type of gamma secretase inhibitor. Nirogacestat may be effective in shrinking the size of KS lesions and reducing the spread of lesions.
Primary Outcome
The ORR will be estimated for each dose group and for all groups combined. The 95% confidence intervals will be constructed for the ORR.
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Computed Tomography
- PROCEDURE Chest Radiography
- PROCEDURE Skin Biopsy
- DRUG Nirogacestat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2026-09-17 |
| Est. Completion | 2030-02-17 |
| Phase | Phase 2 |
What is known before NCT07539454 opens enrollment
NCT07539454 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (79% lower).
The record links to 0 conditions, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT07539454 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07539454 about?
NCT07539454 is a clinical study titled "Nirogacestat in Patients With Kaposi Sarcoma". This phase II trial studies how well nirogacestat works in treating patients with skin Kaposi sarcoma (KS). Several anti-cancer drugs work well in treating KS, but there is no treatment that cures KS. Nirogacestat binds to a protein called gamma secretase, which blocks the activation of other protei...
What is the current status of trial NCT07539454?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2026-09-17. Estimated completion is 2030-02-17.
What interventions are being tested in trial NCT07539454?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Computed Tomography (PROCEDURE), Chest Radiography (PROCEDURE), Skin Biopsy (PROCEDURE), Nirogacestat (DRUG).
Who is sponsoring clinical trial NCT07539454?
This trial is sponsored by AIDS Malignancy Consortium, which has 45 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07539454's enrollment target sits among peer trials
28 1677th of 2000 higher than 304 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI